ENTITY
SMARTSCORE: 3.2/5
Exelixis Inc

Exelixis Inc (EXEL US)

19
Analysis
Health CareUnited States
Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The Company is building a portfolio of compounds it believes could become pharmaceutical products. Exelixis has strategic alliances with pharmaceutical and biotechnology companies.
more
bullishExelixis Inc
20 Jun 2025 07:00

Exelixis Inc.: Will It Be Able To Build On The XB628 & Other Pipeline Expansion Opportunities?

Exelixis recently shared its financial results for the first quarter of 2025, which revealed a mix of promising developments and some areas that...

Logo
257 Views
Share
bullishExelixis Inc
21 Feb 2025 07:00

Exelixis Inc.: Pipeline Expansion & Innovation to Build A Robust Portfolio!

Exelixis reported a robust performance for the fourth quarter and fiscal year 2024, highlighting significant financial growth and ongoing...

Logo
502 Views
Share
bullishExelixis Inc
06 Nov 2024 06:00

Exelixis Inc.: These Are The 4 Biggest Challenges That Justify Our Lack Of Optimism! - Major Drivers

Exelixis Inc. reported its third quarter results for 2024, demonstrating a robust financial and commercial standing, underpinned by significant...

Logo
204 Views
Share
bullishExelixis Inc
16 Oct 2024 06:00

Exelixis Inc.: Expansion Of Cabometyx

Exelixis, Inc. presented its second-quarter 2024 financial results, revealing a period of strong performance and strategic advancements in its...

Logo
300 Views
Share
10 Sep 2024 14:39

Key Updates on Bicara Therapeutics IPO: ~$800M Valuation at the Midpoint and Strong Balance Sheet

Biocon-backed Bicara Therapeutics will go public this week. With top-tier backers, a promising lead program and strong balance sheet, I expect...

Logo
369 Views
Share
x